Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jack Ramage

Gastroenterology Wilmington, NC Medical Doctor

NPI 1841263944 CMS profile 174878

1520 Physicians Dr, Wilmington, NC 28401

Open in the dashboard

General payments

$7,494

46 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jack Ramage of Wilmington, NC is reported in the CMS Open Payments database as having received $7,494 across 46 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19 1
2024 General $1,572 15
2023 General $525 13
2022 General $4,797 4
2021 General $189 4
2020 General $113 5
2019 General $279 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jack Ramage
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Jack Ramage were reported at $19. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Jack Ramage Gastroenterology median Middle half National median
2019 $279 $417 $126–$1,100 $163
2020 $113 $224 $74–$624 $114
2021 $189 $352 $106–$1,054 $132
2022 $4,797 $448 $129–$1,270 $149
2023 $525 $533 $150–$1,390 $160
2024 $1,572 $605 $160–$1,606 $164
2025 $19 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. PENTAX of America, Inc. $6,170 21 payments
  2. Boston Scientific Corporation $1,274 22 payments
  3. Olympus America Inc. $33 2 payments
  4. AbbVie, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $4,550 2 payments
  2. Food and Beverage $2,944 44 payments
Products named General payments · program years 2019–2025
  1. Arietta 750 $3,500 1 payment
  2. ARIETTA 65 $1,513 10 payments
  3. INSPIRA $1,157 10 payments
  4. PENTAX Medical Gastroenterology $1,157 10 payments
  5. PENTAX Medical Gastroenterology $1,157 10 payments
  6. C2 CryoBalloon Focal Controller $1,157 10 payments
  7. C2 CryoBalloon $1,157 10 payments
  8. EXALT Model D $382 4 payments
  9. SPYGLASS $309 5 payments
  10. Acquire $159 1 payment
  11. Other $417 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

756

Median for Gastroenterology: 569

Drug cost

$128,038

Median for Gastroenterology: $104,976

Branded share of claims

4.8%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 12 $90,453
Creon Lipase/Protease/Amylase Brand 12 $19,862
Zenpep Lipase/Protease/Amylase Brand 12 $6,781
Pantoprazole Sodium Generic 456 $6,415
Sucralfate Generic 43 $1,502
Omeprazole Generic 80 $1,324
Famotidine Generic 90 $1,251
Dicyclomine Hcl Generic 14 $270
Ondansetron Hcl Generic 18 $121
Ciprofloxacin Hcl Generic 19 $58

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 116 billing codes

Paid by Medicare

$219,956

Of which drugs: $13,332

Medicare patients

938

Average age 74

Services billed

13,343

473 women, 465 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 36%
Ischemic heart disease 36%
Chronic kidney disease 30%
Depression 30%
Atrial fibrillation 23%
Cancer 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record